NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED
STATES
QUEBEC CITY, Dec. 1, 2016 /CNW Telbec/ - Opsens Inc.
("Opsens" or the "Corporation") (TSXV: OPS) (OTCQX: OPSSF)
is pleased to announce that it has obtained a receipt for its final
short form prospectus (the "Prospectus") for its offering of up to
8,667,000 common shares of the Corporation (the "Shares") at a
price of $1.50 per Share for a
maximum gross proceeds of approximately $13,000,500 (the "Offering"). The Offering will
be conducted on a best effort basis through Paradigm Capital Inc.
("Paradigm"), acting as lead agent, and including RBC Capital
Markets and M Partners Inc. (collectively with Paradigm, the
"Agents").
The Corporation has agreed to grant the Agents an option to
cover over-allotments and for market stabilization purposes (the
"Over-Allotment Option"), which will allow the Agents to arrange
for purchasers to acquire up to an additional 1,300,000 Shares
under the Offering. The Over-Allotment Option will be exercisable,
in whole or in part, at any time up to 30 days after the closing of
the Offering.
The Corporation intends to use the net proceeds of the Offering
to execute the commercialization and marketing strategy of its
Fractional Flow Reserve products ("FFR"), to fund research and
product development and to fund its working capital.
The Offering is being made pursuant to the Prospectus which has
been filed in each of the provinces of
Quebec, Ontario, Alberta and British Columbia.
A copy of the Prospectus is available on SEDAR
at www.sedar.com.
The Offering is expected to close on or about December 8, 2016 and is subject to certain
customary closing conditions. The TSX Venture Exchange ("TSXV") has
conditionally approved the listing of the Shares to be issued
pursuant to the Prospectus.
This press release does not constitute an offer of securities
for sale in the United States or to "U.S. persons" ("U.S.
persons"), as such term is defined in Regulation S promulgated
under the United States Securities Act of 1933, as amended (the
"U.S. Securities Act"). The securities being offered have not been,
nor will be, registered under the U.S. Securities Act or any state
securities laws, and may not be offered or sold in the United
States or to U.S. persons absent registration or an applicable
exemption from such registration requirements.
About Opsens Inc. (www.opsens.com or
www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional
cardiology. Opsens offers an advanced optical-based pressure
guidewire (OptoWire) that aims at improving the clinical outcome of
patients with coronary artery disease. Opsens is also involved in
industrial activities. The Corporation develops, manufactures and
installs innovative fibre optic sensing solutions for critical
applications, such as the monitoring of oil wells and other
demanding industrial applications.
Except for historical information, this press release may
contain "forward-looking statements" and "forward-looking
information" within the meaning of applicable securities laws that
reflect Opsens' current expectation regarding future events,
including, without limitation the use of the net proceeds of the
Offering and the timing and completion of the Offering.
Forward-looking statements contained in this press release involve
known and unknown risks, uncertainties and other factors that may
cause actual results, performance and achievements of Opsens to be
materially different from any future results, performance or
achievements expressed or implied by the said forward-looking
statements. Opsens expressly disclaims any intention to update or
revise any forward-looking statements and information whether as a
result of new information, future events or otherwise, other than
as required by law.
Neither TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this release.
SOURCE OPSENS INC.